Asset Details
Do you wish to reserve the book?
Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer
Do you wish to request the book?
Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer
2017
Overview
Capecitabine monotherapy as palliation for advanced colorectal cancer (CRC) is generally well tolerated. Adding erlotinib, an EGFR-tyrosine kinase inhibitor, might improve efficacy versus capecitabine alone. 82 patients received capecitabine alone (Arm 1) or capecitabine with erlotinib (Arm 2).
Median time-to-progression (TTP) in Arm 1 was 7.9 months versus 9.2 in Arm 2. In
-wild type (WT) patients TTP was 8.4 and 11.7 months in Arms 1 and 2, respectively. In
-mutated patients TTP was 7.4 and 1.9 months in Arms 1 and 2, respectively (p = 0.023). Arm 2
-WT patients, left-sided primaries, had an overall survival of 16.0 versus 12.1 months in right-sided primaries.
Adding erlotinib to capecitabine increased TTP by 3.2 months in
-WT patients. This study suggests that erlotinib harms patients with
-mutated advanced CRC while it may provide benefit to those with
-WT CRC. Further study of EGFR-tyrosine kinase inhibitors in patients with left-sided
-WT CRC is warranted.
Publisher
Future Medicine Ltd
Subject
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Capecitabine - administration & dosage
/ Capecitabine - therapeutic use
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - mortality
/ Colorectal Neoplasms - pathology
/ Diarrhea
/ elderly
/ Erlotinib Hydrochloride - administration & dosage
/ Female
/ frail
/ Humans
/ Male
/ Mutation
/ Patients
/ Proto-Oncogene Proteins p21(ras) - genetics
/ Tumors
